Using a pre-clinical ovarian cancer mouse model, the combination of vaccine and antigen-armed oncolytic Maraba virus elicited robust tumor-specific CD8+ T cell responses and led to unique immunological changes that correlated with improved clinical outcome of ovarian cancer patients (124). The gene discussed is CD8A; the disease is ovarian carcinoma.